Literature DB >> 23935293

Prevalence of thrombophilic mutations in patients with unprovoked thromboembolic disease. A comparative analysis regarding arterial and venous disease.

E Mandala1, C Lafaras, C Tsioni, M Speletas, A Papageorgiou, D Kleta, T Dardavessis, G Ilonidis.   

Abstract

BACKGROUND: Thromboembolic disease (TED) represents one of the main reasons of morbitity and mortality in Western World. Venous and arterial thrombotic disorders have long been viewed as separate pathophysiological entities. However, in recent times the separate nature of arterial and venous thrombotic events has been challenged. Although inherited thrombophilia's predominant clinical manifestation is venous thrombosis, its contribution to arterial thrombosis remains controversial. Purpose  of  the  study  was  to  evaluate  the  prevalence  of  the  most common  thrombophilic  mutations, FV Leiden G1691A-FVL and FII G20210A-PTM and to assess  the  differences between venous, arterial and mixed thrombotic events. Testing  for polymorphism MTHFR C677T and  antithrombin,  protein  C  and  protein  S was also performed. Correlations with  dyslipidemia, smoking, obesity, homocysteine and antiphospholipid antibodies were made.
METHODS: 515 patients with unprovoked TED, 263 males, median age 44 years, were studied. Patients were divided into three groups: 258 with venous thrombosis (group A), 239 with arterial (group B) and 18 with mixed episodes (group C). All patients were interviewed regarding family history of TED, origin, smoking and dyslipidemia. Body mass index (BMI) had been calculated. Molecular assessment of the FVL, PTM and MTHFR C677T was performed. Antithrombin, protein C, protein S, APCR, homocysteine, antiphospholipid antibodies and lipid profile were also measured.
RESULTS: The population studied was homogenous among three groups as regards age (p=0.943), lipid profile (p=0.271), BMI (p=0.506), homocysteine (p=0.177), antiphospholipid antibodies (p=0.576), and positive family history (p=0.099). There was no difference in the prevalence of FVL between venous and arterial disease (p=0.440). Significant correlation of PTM with venous TED was found (p=0.001). The number of positive and negative for MTHFR presented statistically significant difference with a support in arterial disease (p=0.05). Moreover, a 2-fold increase in the risk of venous thrombosis in FVL positive patients (odds ratio: 2.153) and a positive correlation of homocysteine levels with MTHFR C677T (p<0.001) was found.
CONCLUSIONS: Correlation of PTM with venous thrombosis was established. Analysis showed no difference in prevalence of FVL between venous and arterial thrombosis, indicating that FVL might be a predisposing factor for arterial disease. A significant increase in MTHFR C677T prevalence in arterial disease was found. In conclusion, young patients with unprovoked arterial disease should undergo evaluation for thrombophilic genes. Identification of these mutations is important in the overall assessment and management of patients at high risk. Findings will influence the decisions of stratified approaches for antithrombotic therapy either primary or secondary thromboprophylaxis, the duration of therapy, the potential for avoiding clinical thrombosis by risk factor modification and the genetic counselling of family members. However, further studies are needed to clarify the nature of the association regarding venous and arterial thrombotic events.

Entities:  

Keywords:  arterial thromboembolic disease; thrombophilic mutations; unprovoked thromboembolic disease; venous thromboembolic disease

Year:  2012        PMID: 23935293      PMCID: PMC3738733     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  35 in total

1.  An association between atherosclerosis and venous thrombosis.

Authors:  Paolo Prandoni; Franca Bilora; Antonio Marchiori; Enrico Bernardi; Francesco Petrobelli; Anthonie W A Lensing; Martin H Prins; Antonio Girolami
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH.

Authors:  J T Brandt; L K Barna; D A Triplett
Journal:  Thromb Haemost       Date:  1995-12       Impact factor: 5.249

3.  Inherited Thrombophilia due to Factor V Leiden Mutation.

Authors: 
Journal:  Mol Diagn       Date:  1998-03

4.  Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies.

Authors:  A Eliasson; D Bergqvist; M Björck; S Acosta; N H Sternby; M Ogren
Journal:  J Thromb Haemost       Date:  2006-08-01       Impact factor: 5.824

5.  Recurrence rate after a first venous thrombosis in patients with familial thrombophilia.

Authors:  Carla Y Vossen; Isobel D Walker; Peter Svensson; Juan C Souto; Inge Scharrer; F Eric Preston; Gualtiero Palareti; Ingrid Pabinger; Felix J M van der Meer; Mike Makris; Jordi Fontcuberta; Jacqueline Conard; Frits R Rosendaal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-23       Impact factor: 8.311

Review 6.  Familial thrombophilia: a complex genetic disorder.

Authors:  B P Koeleman; P H Reitsma; R M Bertina
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

7.  Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment.

Authors:  O Salomon; D M Steinberg; A Zivelin; S Gitel; R Dardik; N Rosenberg; S Berliner; A Inbal; A Many; A Lubetsky; D Varon; U Martinowitz; U Seligsohn
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

Review 8.  Venous thromboembolism: disease burden, outcomes and risk factors.

Authors:  J A Heit
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 9.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

10.  Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study.

Authors:  Jeppe Frederiksen; Klaus Juul; Peer Grande; Gorm B Jensen; Torben V Schroeder; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

View more
  2 in total

1.  Multiple thrombophilia mutations as a possible cause of premature myocardial infarction.

Authors:  Gabriela Dostálová; Jan Bělohlávek; Zuzana Hlubocká; Kristýna Bayerová; Petra Bobčiková; Tomáš Kvasnička; Jan Kvasnička; Aleš Linhart; Debora Karetová
Journal:  Wien Klin Wochenschr       Date:  2017-04-05       Impact factor: 1.704

2.  Prevalence and Multiplicity of Thrombophilia Genetic Polymorphisms of F V, MTHFR, F II, and PAI -I: A Cross-Sectional Study on a Healthy Jordanian Population.

Authors:  Nabil Al-Zoubi; Nasr Alrabadi; Khalid Kheirallah; Ahmad Alqudah
Journal:  Int J Gen Med       Date:  2021-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.